The patents are valid through 2026-2032.
The granted claims include a class of selective 5-HT6 compounds and H3 inverse agonist compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders. Earlier this month, the company announced it had got similar patents in three countries.
According to the U.S. Food and Drug Administration, a new chemical entity (NCE) is a drug that contains no active moiety that has been approved by the FDA in any other application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act.
Neurodegeneration is the umbrella term for the progressive loss of structure or function of neurons, including death of neurons. Many neurodegenerative diseases including amyotrophic lateral sclerosis, Parkinson’s, Alzheimer’s, and Huntington’s occur as a result of neurodegenerative processes.
With these new patents, Suven has a total of nineteen granted patents from India and Japan each.
“The grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” said Venkat Jasti, CEO of Suven.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing pharmaceutical products, which are class CNS therapies through the use of GPCR targets.
Suven has 3 clinical stage compounds, a Phase 2 undergoing candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 undergoing candidate SUVN-D4010 for Alzheimer’s disease and Schizophrenia. In addition, the Company has ten internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.